Five research organisations from the EU and South Korea signed today a letter of intent (LOI) for international joint research on COVID-19 treatment. This agreement covers the exchange of clinical and nonclinical trial information related to their research on COVID-19 treatment using the repurposed Raloxifene molecule.
MILAN (Reuters) - Italy’s main medicines regulator gave the go-ahead on Tuesday for human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may also help reduce COVID-19 symptoms and make patients less infectious.
The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to treat paucisymptomatic Covid-19 patients.
The study, led by the National Institute for Infectious Diseases “L. Spallanzani” in Rome, Italy, will assess the safety and efficacy of raloxifene in paucisymptomatic patients infected by the Sars-CoV-2 virus. The Clinical Trial also involves the IRCSS Humanitas in Milan.
The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to treat paucisymptomatic Covid-19 patients.
Cadila Pharms Generic Raloxifene Hydrochloride Receives Approval in US
Enforcement Report - Week of February 19, 2020
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.
The National Institute for Health and Care Excellence has now published updated familial breast cancer guidelines which advocate the use of three medicines to reduce the risk of developing the disease.
The objective of this research activity was to formulate and evaluate Raloxifene Hydrochloride (RLX HCl) tablets (BCS class II drug) with enhanced aqueous solubility thereby achieving a formulation with improved dissolution characteristics. Tablets were prepared by incorporating excipients such as disintegrant, solubilizer, wetting agent and evaluated for various pre compression and post compression parameters. Also assay and in-vitro dissolution studies were performed. Formula RLX HCl 27 containing disintegrant Ac-di-sol® (15 mg-intragranular and 5 mg- extragranular) and solubilizer Dimethyl Sulfoxide (DMSO- 10 mg) was selected as the best optimised formula. Optimised formula was scaled up and stability studies were carried out according to the stability protocol. The results indicated that the formulation was stable and had improved dissolution profile as compared to marketed tablet.